Veeva Systems (VEEV) Could Be 16% Undervalued As IQVIA And AI News Draw Focus

IQVIA deal and AI push bring Veeva Systems into focus

Veeva Systems (VEEV) just saw its clinical software suite selected by IQVIA as an enterprise standard across clinical development studies, extending their existing EDC partnership and putting fresh attention on the stock.

The company is also promoting a detailed AI roadmap for clinical, regulatory, safety, and quality operations, which gives investors another angle to assess how its platform approach could influence customer adoption and long term competitiveness.

Investor attention has followed the headlines. Veeva Systems’ share price return has surged 7.8% over the past week and 22.7% over the past month, feeding into a 78.5% 90 day share price return, while the 3 year total shareholder return of 64.6% points to momentum that extends well beyond the latest IQVIA and AI announcements.

Scan beyond Veeva Systems to discover other life sciences and healthcare software players with strong fundamentals and potential momentum in our hand picked 37 healthcare AI stocks

After a 78.5% 90 day surge and a last close of US$320.55 that now sits above the average analyst target, Veeva Systems forces a choice. Do you accept today’s price, or wait for a reset before building a position?

Most Popular Narrative: 16% Undervalued

Veeva Systems is trading at $320.55 against a widely followed fair value estimate of $383.14, which frames the current premium P/E and recent IQVIA news in a different light for investors weighing fresh exposure.

Veeva’s attraction is not simply that it sells software to pharmaceutical companies.

Its attraction is that it sits inside workflows where reliability, compliance, historical data, and institutional trust matter enormously.

See why 52 investors see Veeva Systems as 16% undervalued.

Result: Fair Value of $383.14 (UNDERVALUED)

Still, two things can trip this Veeva Systems thesis fast: a slowdown in life sciences software budgets, and weaker Falcon AI adoption than investors currently expect.

Find out about the key risks to this Veeva Systems narrative.

Another view on Veeva Systems’ valuation

That user narrative leans on a discounted cash flow style view that points to Veeva Systems being 16% below a fair value of $383.14. The market is telling a different story. At $320.55, the stock trades on a P/E of 51.1x versus a global healthcare services average of 27.3x and a fair ratio of 32.4x. This means a lot of optimism is already embedded in the price.

For readers comparing these signals, the key question is simple: does the quality of Veeva’s earnings and business model justify paying so far above that fair ratio, or is this where valuation risk starts to build?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on Veeva Systems leave you torn, act quickly, take a closer look at the underlying data, and weigh both sides clearly with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Veeva Systems?

If Veeva Systems has your attention but you are not ready to stop at one opportunity, you may want to broaden your research with a few targeted stock ideas.

• Target resilience by focusing on companies that pair strong fundamentals with low perceived risk using our 31 resilient stocks with low risk scores.
• Hunt for quality at a potential discount by scanning companies that look attractively priced on fundamentals through the 33 high quality undervalued stocks.
• Pinpoint dependable income ideas by reviewing a curated 7 dividend fortresses that combine higher yields with a focus on durability.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com